Paradigm’s PPS Shows Sustained Clinical and Structural Benefits in Canine Osteoarthritis Study

Paradigm Biopharmaceuticals ( (AU:PAR) ) has issued an announcement.

Paradigm Biopharmaceuticals announced that a Paradigm-supported study of pentosan polysulfate sodium in dogs with naturally occurring osteoarthritis has been published in the peer-reviewed journal PLOS One. The collaborative trial with the University of Melbourne assessed a six-week course of subcutaneous PPS in companion dogs with established joint disease of the stifle and elbow, using pain scores, gait analysis, MRI and serum biomarkers over a 26-week follow-up.

The randomized, placebo-controlled exploratory study showed that PPS-treated dogs had sustained reductions in chronic pain through 26 weeks, while placebo-treated dogs experienced worsening pain. Objective gait analysis demonstrated progressive normalization of gait symmetry and improved weight bearing in the PPS group, indicating better joint function and reduced lameness.

MRI data revealed stabilization and modest increases in cartilage volume in PPS-treated dogs at weeks 8 and 26, compared with continued cartilage loss in the placebo group. Together with changes in bone and cartilage turnover biomarkers, these structural results support a potential disease-modifying effect of PPS and strengthen the relevance of the canine osteoarthritis model as a translational analogue for longer-term human outcomes.

The publication provides peer-reviewed validation that PPS can deliver durable clinical, functional and structural benefits in a model of naturally occurring, age-related osteoarthritis highly regarded by the pharmaceutical industry. This supports Paradigm’s positioning of PPS as a candidate disease-modifying therapy for osteoarthritis and may bolster confidence among regulators, clinicians and investors in the company’s late-stage development strategy.

The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd is an ASX-listed, late-stage drug development company focused on delivering new therapies to address unmet medical needs. The company’s lead work involves pentosan polysulfate sodium (PPS), targeting osteoarthritis and related musculoskeletal conditions, with a focus on translating promising preclinical and veterinary findings into human treatments.

Average Trading Volume: 915,084

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$125.8M

Find detailed analytics on PAR stock on TipRanks’ Stock Analysis page.